{"entity":{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","aka":[],"tldr":"Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.","summary":"Martin Dreyling leads the European Mantle Cell Lymphoma Network, whose MCL Younger and Elderly trials established cytarabine-based induction with autologous transplant and rituximab maintenance, and was principal investigator of TRIANGLE, which showed adding ibrutinib to first-line therapy improves outcomes and that transplant adds nothing once ibrutinib is given, a shift toward chemotherapy-light care. He chairs ESMO lymphoma guideline work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dreyling%20M%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"tags":["lymphoma","mantle-cell","cooperative-group"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of the Lymphoma Program, LMU University Hospital Munich; Chair, European MCL Network","institutionId":"lmu-munich","specialisms":["Mantle cell lymphoma","First-line therapy","BTK inhibitors","European cooperative trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dreyling%20M%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"papers":[{"title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00184-0"},{"title":"Treatment of older patients with mantle-cell lymphoma (MCL Elderly)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1200920"}]},"route":"/people/martin-dreyling/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"institution":[{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/"}],"trial":[{"id":"elara","kind":"trial","name":"ELARA","route":"/trials/elara/"},{"id":"shine","kind":"trial","name":"SHINE","route":"/trials/shine/"}],"paper":[{"id":"paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","kind":"paper","name":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","route":"/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/"},{"id":"paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022","kind":"paper","name":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","route":"/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/"},{"id":"paper-elara-tisagenlecleucel-follicular-nat-med-2022","kind":"paper","name":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","route":"/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}